Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 11, 2013, Pages 1452-1459

  Bas M ^a   Greve, J ^b   Hoffmann, T K ^b   Reshef, A ^c   Aberer, W ^d   Maurer, M ^e   Kivity, S ^f   Farkas, H ^g   Floccard, B ^h   Arcoleo, F ⁱ   Martin, L ^j   Sitkauskiene, B ^k   Bouillet, L ^l   Schmid Grendelmeier, P ^m   Li, H ⁿ   Zanichelli, A ^o  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c SHEBA MEDICAL CENTER   (Israel)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^g SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^j ANGERS UNIVERSITY HOSPITAL   (France)

^k LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁿ Shire Human Genetic Therapies   (United States)

^o UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

bradykinin B2 receptor antagonist; For Angioedema Subcutaneous Treatment 2 (FAST 2); hereditary angioedema; icatibant; open label extension phase

Indexed keywords

ICATIBANT;

ADULT; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE HEREDITARY ANGIOEDEMA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; SWALLOWING; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; VOICE CHANGE;

BRADYKININ B2 RECEPTOR ANTAGONIST; FOR ANGIOEDEMA SUBCUTANEOUS TREATMENT-2 (FAST-2); HEREDITARY ANGIOEDEMA; ICATIBANT; OPEN-LABEL EXTENSION PHASE;

ADULT; ANGIOEDEMAS, HEREDITARY; BRADYKININ; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, BRADYKININ B2; RECURRENCE; TREATMENT OUTCOME;

EID: 84887440357     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12244     Document Type: Article

References (24)

1. Bork K, Staubach P, Eckardt AJ, Hardt J,. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 Inhibitor deficiency. Am J Gastroenterol 2006; 101: 619-627.
2. Longhurst HJ,. Management of acute attacks of hereditary angioedema: potential role of icatibant. Vasc Health Risk Manag 2010; 6: 795-802.
3. Bernstein JA, Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz DS, et al. Hereditary angioedema: validation of the end point time to onset of relief by correlation with symptom intensity. Allergy Asthma Proc 2011; 32: 36-42.
4. Longhurst HJ, Farkas H, Craig T, Aygören-Pürsün E, Bethune C, Bjorkander J, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010; 6: 22.
5. Davis AE III,. The pathophysiology of hereditary angioedema. Clin Immunol 2005; 114: 3-9.
6. Donaldson VH, Evans RR,. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C′1-esterase. Am J Med 1963; 35: 37-44.
7. Davis AE III,. C1-inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595-628.
8. Cugno M, Nussberger J, Cicardi M, Agostoni A,. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3: 311-317.
9. Kaplan AP, Ghebrehiwet B,. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 2010; 47: 2161-2169.
10. Kaplan AP, Joseph K,. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 193-204.
11. Davis AE III,. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100: S7-S12.
12. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A,. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005; 99: 6-38.
13. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A,. Plasma bradykinin in angio-edema. Lancet 1998; 351: 1693-1697.
14. Nussberger J, Cugno M, Cicardi M, Agostoni A,. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999; 104: 1321-1322.
15. Zuraw BL,. Current and future therapy for hereditary angioedema. Clin Immunol 2005; 114: 10-16.
16. Maurer M, Bader M, Bas M, Bossi F, Cicardi M, Cugno M, et al. New topics in bradykinin research. Allergy 2011; 66: 1397-1406.
17. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W,. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007; 119: 1497-1503.
18. Cicardi M, Banerji A, Bracho F, Malbràn A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
19. 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107: 529-537.
20. 2-receptor antagonist icatibant. Allergy 2006; 61: 1490-1492.
21. Aberer W,. Hereditary angioedema treatment options: the availability of new therapies. Ann Med 2012; 44: 523-529.
22. Riedl MA, Hurewitz DS, Levy R, Busse PJ, Fitts D, Kalfus I,. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. Ann Allergy Asthma Immunol 2012; 108: 49-53.
23. Craig TJ, Bewtra AK, Hurewitz D, Levy R, Janss G, Jacobson KW, et al. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. Allergy Asthma Proc 2012; 33: 354-361.
24. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.